CA1179372A - 1-branched-alkyl-3-(2-haloethy)-3-nitrosoureas as novel antitumor agents - Google Patents
1-branched-alkyl-3-(2-haloethy)-3-nitrosoureas as novel antitumor agentsInfo
- Publication number
- CA1179372A CA1179372A CA000347028A CA347028A CA1179372A CA 1179372 A CA1179372 A CA 1179372A CA 000347028 A CA000347028 A CA 000347028A CA 347028 A CA347028 A CA 347028A CA 1179372 A CA1179372 A CA 1179372A
- Authority
- CA
- Canada
- Prior art keywords
- hal
- chlorine
- compound
- general formula
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 title description 7
- 239000002246 antineoplastic agent Substances 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 24
- 230000008569 process Effects 0.000 claims abstract description 22
- 239000000460 chlorine Substances 0.000 claims abstract description 19
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 16
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 11
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000011737 fluorine Substances 0.000 claims abstract description 10
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract description 7
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims abstract description 6
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims abstract description 6
- 125000005244 neohexyl group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims abstract description 6
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- UOAFGUOASVSLPK-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(2,2-dimethylpropyl)-1-nitrosourea Chemical compound CC(C)(C)CNC(=O)N(N=O)CCCl UOAFGUOASVSLPK-UHFFFAOYSA-N 0.000 claims 1
- GEWXJIPJMZRTJM-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(2-methylpropyl)-1-nitrosourea Chemical compound CC(C)CNC(=O)N(N=O)CCCl GEWXJIPJMZRTJM-UHFFFAOYSA-N 0.000 claims 1
- IORTWKXUPMHXON-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(3,3-dimethylbutyl)-1-nitrosourea Chemical compound CC(C)(C)CCNC(=O)N(N=O)CCCl IORTWKXUPMHXON-UHFFFAOYSA-N 0.000 claims 1
- DYGPLBQZIAHCMX-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(3-methylbutyl)-1-nitrosourea Chemical compound CC(C)CCNC(=O)N(N=O)CCCl DYGPLBQZIAHCMX-UHFFFAOYSA-N 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 12
- 239000012948 isocyanate Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 108060008539 Transglutaminase Proteins 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 102000003601 transglutaminase Human genes 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 150000002513 isocyanates Chemical class 0.000 description 8
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 229940090044 injection Drugs 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical class NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 6
- 101000874159 Mus musculus Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Proteins 0.000 description 5
- -1 neohexyl isocyanate Chemical class 0.000 description 5
- ZXTNZWUISUXJMB-UHFFFAOYSA-N 1,1-bis(2,2-dimethylpropyl)-3-nitrosourea Chemical compound C(C(C)(C)C)N(C(NN=O)=O)CC(C)(C)C ZXTNZWUISUXJMB-UHFFFAOYSA-N 0.000 description 4
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 4
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 235000010288 sodium nitrite Nutrition 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102100021906 Cyclin-O Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 3
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 231100000315 carcinogenic Toxicity 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229960004132 diethyl ether Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- BCMYXYHEMGPZJN-UHFFFAOYSA-N 1-chloro-2-isocyanatoethane Chemical compound ClCCN=C=O BCMYXYHEMGPZJN-UHFFFAOYSA-N 0.000 description 2
- USXSCBCCYNVIPN-UHFFFAOYSA-N 1-isocyanato-2,2-dimethylpropane Chemical compound CC(C)(C)CN=C=O USXSCBCCYNVIPN-UHFFFAOYSA-N 0.000 description 2
- KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 2
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000007093 Leukemia L1210 Diseases 0.000 description 2
- 208000008342 Leukemia P388 Diseases 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 101150059476 SLC44A3 gene Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 2
- BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- ROMJIXGXOJMKOC-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(2-methylpropyl)urea Chemical compound CC(C)CNC(=O)NCCCl ROMJIXGXOJMKOC-UHFFFAOYSA-N 0.000 description 1
- XDIAMRVROCPPBK-UHFFFAOYSA-N 2,2-dimethylpropan-1-amine Chemical compound CC(C)(C)CN XDIAMRVROCPPBK-UHFFFAOYSA-N 0.000 description 1
- SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- GPWHFPWZAPOYNO-UHFFFAOYSA-N 3,3-dimethylbutan-1-amine Chemical compound CC(C)(C)CCN GPWHFPWZAPOYNO-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 101100005765 Arabidopsis thaliana CDF1 gene Proteins 0.000 description 1
- 101100007579 Arabidopsis thaliana CPP1 gene Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000009127 Glutaminase Human genes 0.000 description 1
- 108010073324 Glutaminase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- YWGHUJQYGPDNKT-UHFFFAOYSA-N hexanoyl chloride Chemical compound CCCCCC(Cl)=O YWGHUJQYGPDNKT-UHFFFAOYSA-N 0.000 description 1
- 230000009097 homeostatic mechanism Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/30—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
- C07C273/1854—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas by reactions not involving the formation of the N-C(O)-N- moiety
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/66—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to halogen atoms or to nitro or nitroso groups
- C07C275/68—N-nitroso ureas
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
A process for preparing a compound of the general formula:
wherein, R is neopentyl, neohexyl, isopentyl or isobutyl and Hal is chlorine or fluorine, the process comprising, nitrosolating a compound of the general formula:
A process for preparing a compound of the general formula:
wherein, R is neopentyl, neohexyl, isopentyl or isobutyl and Hal is chlorine or fluorine, the process comprising, nitrosolating a compound of the general formula:
Description
~ 17937~
~ rhe L)resent invention relates to novel nitrosourea derivatives useEul for their antitumor activity.
In the past decade, the nitrosoureas have gained acceptance as potent antitumor agents (Johnston, _t al., J. Med. Chem., 14:600 (1971)). The accepted mode of action appears to be through the release of isocyanate ln vivo.
The -two compounds most frequently used clinically are l-cyclohexyl-3-(Chloroethyl)-3-nitrosourea(CCNU) and 1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU) which release in vivo an isocyanate derived from the unnitrosated side of the molecule, and an alkylating-agent from the other side.
Numerous studies have been directed toward the meta-bolic products produced ln vlvo and ln itro in aqueous me~dicl, which mainly consist of 2-chloroethanol, vinyl chloride, acetaldehyde, anddichloroethane (Johnston, ~t al., J. Med.
Chem., 18:634 (1975)). It is also known that the N~nitroso-N-alkyl ureido portion of the molecule alkylates DNA
(deoxyribonucleic acid) in vivo and in vitro (Frei, et al., Biochem. J., 174:1031 ~1978)). In fact, it has been shown that the carcinogenic effectiveness of agents such as N-methyl-N-nitrosourea correlate with the extent of alkylation of the guanine moiety in DNA of target tissues at the C~6 atom.
Alkylation of DNA occurs within an hour after administration of the nitrosourea, and the half-life of the alkylated products is about 24 to 48 ho~rs (Reed, et al., Cancer Res., 35:568 (1975)). The study indicated that low doses of nitrosoureas pose only a small threat as mutagens, and hence, are not significantly carcinogenic. From this it may be postulated that the more transglutaminase-specific ,'r ~ ~937~
(see below) tlle isocyanate resulting from decomposition of the nitrosourea, the lower the required dose, resulting in a reduced risk of carcinogenesis Erom the antitumor agent.
It has recently been showrl that a number of isocyan-a-tes are potent inhibitors of the enzyme transglutaminase (Gross, et al., J. Biol. Chem., 250:7693 (l975)), a calcium-dependent enzyme which cataly~es the lysine-glutamine cross-linking of certain proteins present on neoplastic cell surfaces.
This enzyme has been implicated in the uncontrolled prolifera-tion of cancer cells (Yancey and ~aki, Ann. N.Y. Acad. Sci., 202:344 (1972)). It has been proposed that these cross:linked proteins form an extracellular coating causing the cell to be unrecognized by the cellular immune system, thus pre~ent:ing normal destruction of foreign neoplastic -tissue. The enzyme is fairl~ speciEic toward glu-tamine residues ~s su~s-trates, and isocyanates resembling these residues have been ~ound to be the mos-t effective inhibitors (Gross, et al., ~. Biol.
Chem., 250:7693 (1975)).
The structure oE the active site of the -transgluta-minase has been found to contain the pentapeptide sequence --Tyr-Gly-Gln-Cys-Trp-- and has the shape of a pocket approximately 5 x 5 Angstroms tFo1k and Cole, J. ~iol. Chem., 241:3238 (1966)).
According -to the hypothesis upon which the invention is based, a superior inhibitor of transglutaminase would have, in view of the sequence and size indicated above, hydrophobic moieties directed away from, but in proximity to, the pocket at the active site. Two possible inhibitors meeting these criteria are neopen-tyl isocyanate (I) and neohexyl isocyanate (II) which can be seen to resemble 1 ~7g3P~2 gluta111ine (III) in size:
Ctl3 CH3 CH3-f-CE12-N-C=OC113~ -C~12-CH2-N=C=O
Ctl3 CH3 (I) (~I) 1 ~12 H-C-CH -CH - J o j=0 NH2 0~1 (III) ~he hypothesis oE the invention is supportecl by the -fact that t-butyl groups, or other hydrophobic groups, attachecl to the be-ta- or gamma-carbon of glutamic acid produce superior substrates for transglutaminase (Gross and Folk, J. Biol. Chem., 248:130 (1973)). Ester analogs oE these compounds are also substrates ~Gross and Folk, J. Biol. Chem., 249:3021 (l974)).
It has been shown that isocyanates inhibi-t the transglutaminase through alkyl thiocarbamate ester formation through the single active site sulfhydryl group (Gross, et al., J. Biol. Chem., 250:7693 (1975)):
I 179~72 H O
l 11 R-SH + R'-N=C-O ~R'-N-C-SR
Bis-(neopentyl)-N-nitrosourea (IV) CH O CH
CH3-f-CH2-W-C-NH-CH2-f-CH3 (IV) was synthesized as a compound which woulcl release neopentyl isocyanate (I) ln _vo resulting in inhibition of trans~
glutaminase. However, the limited solubility of this com-pound prevented its clinical evaluation.
Recent studies have shown -that the activity of nitrosoureas is markedly enhanced by the presence of the
~ rhe L)resent invention relates to novel nitrosourea derivatives useEul for their antitumor activity.
In the past decade, the nitrosoureas have gained acceptance as potent antitumor agents (Johnston, _t al., J. Med. Chem., 14:600 (1971)). The accepted mode of action appears to be through the release of isocyanate ln vivo.
The -two compounds most frequently used clinically are l-cyclohexyl-3-(Chloroethyl)-3-nitrosourea(CCNU) and 1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU) which release in vivo an isocyanate derived from the unnitrosated side of the molecule, and an alkylating-agent from the other side.
Numerous studies have been directed toward the meta-bolic products produced ln vlvo and ln itro in aqueous me~dicl, which mainly consist of 2-chloroethanol, vinyl chloride, acetaldehyde, anddichloroethane (Johnston, ~t al., J. Med.
Chem., 18:634 (1975)). It is also known that the N~nitroso-N-alkyl ureido portion of the molecule alkylates DNA
(deoxyribonucleic acid) in vivo and in vitro (Frei, et al., Biochem. J., 174:1031 ~1978)). In fact, it has been shown that the carcinogenic effectiveness of agents such as N-methyl-N-nitrosourea correlate with the extent of alkylation of the guanine moiety in DNA of target tissues at the C~6 atom.
Alkylation of DNA occurs within an hour after administration of the nitrosourea, and the half-life of the alkylated products is about 24 to 48 ho~rs (Reed, et al., Cancer Res., 35:568 (1975)). The study indicated that low doses of nitrosoureas pose only a small threat as mutagens, and hence, are not significantly carcinogenic. From this it may be postulated that the more transglutaminase-specific ,'r ~ ~937~
(see below) tlle isocyanate resulting from decomposition of the nitrosourea, the lower the required dose, resulting in a reduced risk of carcinogenesis Erom the antitumor agent.
It has recently been showrl that a number of isocyan-a-tes are potent inhibitors of the enzyme transglutaminase (Gross, et al., J. Biol. Chem., 250:7693 (l975)), a calcium-dependent enzyme which cataly~es the lysine-glutamine cross-linking of certain proteins present on neoplastic cell surfaces.
This enzyme has been implicated in the uncontrolled prolifera-tion of cancer cells (Yancey and ~aki, Ann. N.Y. Acad. Sci., 202:344 (1972)). It has been proposed that these cross:linked proteins form an extracellular coating causing the cell to be unrecognized by the cellular immune system, thus pre~ent:ing normal destruction of foreign neoplastic -tissue. The enzyme is fairl~ speciEic toward glu-tamine residues ~s su~s-trates, and isocyanates resembling these residues have been ~ound to be the mos-t effective inhibitors (Gross, et al., ~. Biol.
Chem., 250:7693 (1975)).
The structure oE the active site of the -transgluta-minase has been found to contain the pentapeptide sequence --Tyr-Gly-Gln-Cys-Trp-- and has the shape of a pocket approximately 5 x 5 Angstroms tFo1k and Cole, J. ~iol. Chem., 241:3238 (1966)).
According -to the hypothesis upon which the invention is based, a superior inhibitor of transglutaminase would have, in view of the sequence and size indicated above, hydrophobic moieties directed away from, but in proximity to, the pocket at the active site. Two possible inhibitors meeting these criteria are neopen-tyl isocyanate (I) and neohexyl isocyanate (II) which can be seen to resemble 1 ~7g3P~2 gluta111ine (III) in size:
Ctl3 CH3 CH3-f-CE12-N-C=OC113~ -C~12-CH2-N=C=O
Ctl3 CH3 (I) (~I) 1 ~12 H-C-CH -CH - J o j=0 NH2 0~1 (III) ~he hypothesis oE the invention is supportecl by the -fact that t-butyl groups, or other hydrophobic groups, attachecl to the be-ta- or gamma-carbon of glutamic acid produce superior substrates for transglutaminase (Gross and Folk, J. Biol. Chem., 248:130 (1973)). Ester analogs oE these compounds are also substrates ~Gross and Folk, J. Biol. Chem., 249:3021 (l974)).
It has been shown that isocyanates inhibi-t the transglutaminase through alkyl thiocarbamate ester formation through the single active site sulfhydryl group (Gross, et al., J. Biol. Chem., 250:7693 (1975)):
I 179~72 H O
l 11 R-SH + R'-N=C-O ~R'-N-C-SR
Bis-(neopentyl)-N-nitrosourea (IV) CH O CH
CH3-f-CH2-W-C-NH-CH2-f-CH3 (IV) was synthesized as a compound which woulcl release neopentyl isocyanate (I) ln _vo resulting in inhibition of trans~
glutaminase. However, the limited solubility of this com-pound prevented its clinical evaluation.
Recent studies have shown -that the activity of nitrosoureas is markedly enhanced by the presence of the
2-chloroethyl group on the nitrosated side of the compound (Montgomery, Clncer Treat. Rep., 60:651 (1976); Johnston, et al., J. Med. Chem., 9:892 (1966); Farmer, et al., J. Med.
Chem., 21:514 (1978)). Since the 2-chloroethyl group also enhances solubility, it became the group of choice at the
Chem., 21:514 (1978)). Since the 2-chloroethyl group also enhances solubility, it became the group of choice at the
3-position in this study.
According to an aspect of this invention there is provided a process for preparing a compound of the general formula:
Il R- NH- C- N- CH2- CH2- Hal (A) N=O
wherein R is selected from the group consisting of neopentyl, neohexyl, isopentyl and isobutyl and Hal is selected , I
" .
~ ~7937~
from -the group consisting oE chlorine and fluorine, the process comprisiny nitrosolating a compound of the general formula:
R- NH- C -NH- CH2- CH2- Hal with nitrous aci.d.
Compounds having the formula (A) have an'itumor activ-itY and are novel. In accordance with another aspect of the invention such compounds are provided whenever produced by the process aspect of the invention, or by an obvious chemical equivalent thereof.
The following compounds of the invention were synthesized as described in the Experimental section:
o R- NH- C - N- CH2 CH2 Hal N=O
,)o V, R = Neopentyl VI, R = Neohexyl VII, R = Isopentyl VIII, R = Isobutyl Hal = Cl or F
~ 179~72 Chemical studies revealed that the neopentyl and neohexyl isocyanates are remarkahly stable in water-acetone (1:3) at 57 C without substantial amounts being hydroly~ed even after a three-day period at pH 6Ø Both have half-lives of greater than 30 minutes at physiological pH and tempera-ture.
Thus, the branched alkyl groups of the compounds of the invention were selected using the criterion that they should be substrates for, and thus be selective inhibitors of, transglutaminase. As noted above, the work oE Montgomery discloses a single l-branched-alkyl-3-~2-chloroethyl)-3 nitrosourea, namely l-(l-me-thyl-hexyl)-3-(2-chloroethyl)-3-ni-trosourea (IX):
cl~3cf~2c~2cH2c~l2- fH~ NH- C- N- CH2CH2~ Cl (IX) While this compound is a l-branched-alkyl-3-(2-chloroethyl)-3-nitrosourea, it does not fulfill the steric criteria outlined above for optimal inhibitory activi-ty.
It is not desired to limit the invention by the theoretical considerations presented herein, and the above discussion is included merely for purposes of background discussion.
EXPERIMENTAL SECTION
Melting points were determined using a Thomas Hoover capillary melting point appara-tus and are uncorrected.
InErarecl (IR) spectra were obtainecl using a Perkin Elmer 397 spectrophotometer, and NMR (nuclear magnetic resonance) spectra were taken on a Br~ker ~P80DS system with tetramethyl-silane as an internal standard. Elemental analyses were carried out by Calbraith Laboratories, Knoxville, Tennessee.
Butyl acetyl chloride and 3,3 dime-thyl-l-butallol were obtained from Aldrich Chemical Co. and were used wlthout further purification as a result of sa-tisfactory NMR analysis.
1-Neopentyl-3-(2-Chloroethyl~ Urea. Neopentylamine (8.7 g, 0.1 mol) was dissolved in 50 ml of anhydrous diethyl ether and cooled to 5C. 2-Chloroethyl isocyanate (10.5 g, ().1 mol) dissolved in an additional 50 ml of ether was aclded over :30 minutes while maintaining a tempera-ture of less than 1() C.
Stirring continued for an addi-tional hour, ancl ~he cold mixture was filtered and washecl with chilled ether. The compound was dried in a desiccator over sodium hydroxide overnight giving 15.4 g (80%) as a whi-te powder, MP (meltiny point) 90-1C (decomposes). Elemental analysis showed the following:
Calculated Found Carbon 49.97% 49.87%
Hydrogen 8.87% 8.89%
Nitroyen 14.52% 14.54%
Chlorine 18.47~ 18.40%
IR analysis showed bands at 1630/cm (C=O) and 1535/cm (N-C=O). NMR showed a singlet (9H) at 0.8 ppm and a mutliplet (6H) at 3.4 ppm.
1 1 7~372 l-Neopentyl-3-~2-Chloroethyl)-3-Nitr~sourea (V). The entire _ __ _ _ _ yield of l-neopentyl-3-(2-chloroethyl~ urea (0.08 mol) was dissolved in 120 ml of concentrated HCl:ethanol, 2:1 at 5 C
in a 500 ml round bo-ttom flask equipped with magnetic stirrer. Sodium nitrite (5.5 g, 0.08 mol) was dissolved in 30 ml of water and added to the solution over a ten-minute period. Stirring continued for 2 hrs., and the yellow, crystalline precipita-te was filtered and washed with five 100 ml portions of chilled distilled water. The product was dried in vacuo for 18 hrs. giving 15 g (84%~ which melted with decomposition at 52-3C. IR analysis showed peaks at 1730/cm (C=O~ and 1520/cm (C-N-H). NMR showed a singlet (9EI) at 1 ppm, a doublet (2H, J = 6.5 Hz) at 3.3 ppm, a triplet (2H, J -- 6.5 llz) at 3.6 ppm, and a triple-t (2H, J = 6.5 Hz) at 4.2 ppm.
1-Neohexyl-3 ~ . A 5 g quantity of 3,3-dimethyl butylamine (0.5 mol) was dissolved in 30 ml of anhydrous diethyl ether and stirred on an ice bath.
2-Chloroethyl isocyanate (5.25 g, 0.5 mol) dissolved in 15 ml of ether was added maintaining a temperature of 10 C or less, and stirring continued for 2 hrs. Fil-tering the product and washing with four 5 ml portions of chilled ether afforded 6.2 g (60%) which melted at 84C (decomposes). IR
analysis showed peaks at 1625/cm (C-O) and ]580/cm (N-C=O).
NMR: singlet (9H) at 0.9 ppm, multiplet (2H) at 1.3 ppm, multiplet (2H) at 3.2 ppm, multiplet (4H) at 3.5 ppm, singlet (lH) at 5.5 ppm, and singlet ~lH) at 5.7 ppm.
`1~
1 ~79372 _Neohexyl-3-(2-Chloroethyl)-3--Nitrosourea (VI). A 2.07 g (10 mmol) quantity of 1-neohexyl-3-~2-chloroethyl) urea was dissolved in 15 ml of concentrated HCl:ethanol, 2:1, at 10 C, and 690 mg (10 mmol) sodium nitrite dissolved in 3 ml oE water was added. Stirring at 0.5C continued Eor 1.5 hrs.
and the precipita-te was washed with four 25 ml portions of distilled water. After drying in vacuo overnight, 1.7 g (74%) of the product was obtained which meltecl at 43.0-43.5C (decomposes). IR analysis showed peaks at 17C5/cm (C=O) and 1525/cm (C-N=O). NMR: singlet (9H) at 0.9 ppm, mul-tiplet (2H) at 1.3 ppm, symmetrical multiplet (6H) at 3.8 ppm. No evidence of isomeric ma-terial was detected.
l-Isopentyl-3-(2-Chloroethyl) Urea. Isopentylamine (8.7 c3, 0.1 mol) was dissolved in 100 ml of anhydrous ether and cooled to less -than 10C. 2-Chloroethyl isocyana-te (10.5 cJ, 0.1 mol) was dissolved in 20 ml of ether and added to -the rapidly stirring reaction mixture at less than 10C. Stirring was continued for 1 hr. longer and the precipitate was filtered and washed with four 20 ml portions of chilled ether.
After drying in vacuo overnight, 16.5 g (85~) of product was obtained as a white powder, MP 58-9C. IR analysis showed peaks at 1620/cm (C=O) and 1575/cm (N-C=O). NMR showed a doublet (6H, J = 7 Hz) at 0.9 ppm, a triplet (2H,J = 7 Hz) at 1.4 ppm, a multiplet (lH) at 1.8 ppm, a multiplet (lH) at 3.2 ppm, a multiplet (4H) at 3.6 ppm, a singlet (lH) at 5 7 ppm, and a singlet (lH) at 6.0 ppm.
l-Isopentyl-3-(2-Chloroethyl)-3-Nitrosourea (VII). A 1.92 g (10 mmol) quantity of 1-isopentyl-3-(2-chloroethyl~ urea ~.
was dissolved in 15 ml o~ HCl:ethonal, 2:1, and cooled to 5C. Sodium nitrite (690 mg, 10 mrnol) dissolved in 3 ml of water was added in portions with stirring, after which stirring was continued for an additional 2 hrs. The mixture was filtered and 50 ml of water was added. Extracting with two 20 ml portions of ethyl acetate Eollowed by evaporation of the solvent afforded the product as an oil which did not solidify on standing. Similar resul-ts were obtained using 98% formic acid as the solvent. IR analysis showed peaks at 1705/cm (C=O) and 1525/cm (N-C=O~. NMR analysis showed a doublet (6H, J = 7 Hz) at 0.9 ppm, a triplet (2H, J = 7 Hz) at 1.4 ppm, a multiplet (lH) at 1.8 ppm, a multiple-t (6H) at 3.8 ppm, and a singlet (lH) a-t 7.4 ppm.
l-Isobut~l-3-(2-Chlor ~ ~rea. Isobu-tylamine ~7.3 ~, 0.1 mol) was dissolved in 20 ml of die-thyl ether and cooled to less than 5 C. Chloroethyl isocyana-te (10.5 9, 0.1 mol) dissolved in 15 ml of ether was added maintaining a tempera-ture between 0 and 5 C with vigorous stirring. Stirring was continued for an additional 2 hrs. the mixture was cooled to -5C, and the product (4.1 g, 46~) was filtered and dried in vacuo for 18 hrs. over KOH, MP 79.5 C (decomposes).
IR analysis showed peaks at 1630/cm (C=O) and 1585/cm (N-C=O).
NMR: Doublet at 0.9 ppm (J = 6.4 Hz), multiplet (lH) a-t 2.1 ppm, quartet (2H) at 2.9 ppm (J = 6.4 Hz), multiplet (4H) at 3.5 ppm.
l-Isobutyl-3-(2-Chloroethyl)-3-Nitrosourea (VIII). A 2 g (11.2 mmol) quantity of 1-isobutyl-3-(2-chloroethyl) urea was dissolved in 25 ml of concentrated HCl:e-thanol, 2:1, .
.-1 1~9372 and cooled to S C. A solution of 773 mg ~11.2 mmol) o~ sodium nitrite in 5 ml of water was added in portions and the mixture was stirred at this temperature for 2 hrs. The crystalline yellow solid was filtered and dried in vacuo overnight giving 1.6 g (70~) oE the product, MP 51C
(decomposes). IR analysis showed peaks at 1705~cm (C=O) and 1525/cm (C-N=O). NMR: Doublet (6H, J = 6.8 Hz) at 0.9 ppm, multiplet (1~l) at 2.0 ppm, multiplet (6H) at 3.7 ppm.
1-Branched-alkyl-3-(2-fluoroethyl)-3-nitrosoureas. Syntheses corresponding to those described above may be performed using the 2-fluoroethyl compounds to produce the l-branched-alkyl-3-(2-fluoroethyl)-3-nitrosoureas.
CLINICAL STUDIES
Exper1ment I
A single dose of l-neopentyl-3-(~-chloroethyl)-3-nitrosourea (NCNU) was injected intraperitoneally (ip) in CDF1 mice which had been implanted ip two days earlier with approximately 10 x 105 murine leukemia L1210 tumor cells.
The NCNU was dissoIved in Emulphor EL-620 (polyoxyethylated;
GAF Corporation, New York, N.Y.) and raised to the desired volume with 0.85~ sodium chloride. The increase in median lifespan (ILS) of the test animals above control (untreated) animals is presented in Table I.
* A Trade Mark TABLE I
Effects of Single-Dose Treatment with NCNU Against _ 'l'wo-Day Murine Leukemia L1210 Dose (mg/kg) '~ ILS
_ 100 275 ~
275 +
37.S
Experiment II
The s-tudy of Experiment I was conducted using approximately 5 x 105 murine leukemia P388 tumor c~lls (0.1 ml of a 1:100 dilu-tion). Results are presented in Table II.
TABLE II
.
Effects of Single-Dose Treatment with NCNU Against Two-Day Murine Leukemia P388 Dose (mg/Mouse) % ILS
-2.0 483 +
1.0 91.7 0.5 41.5 , The plus sign indicates that the animals have not yet all died and the experiments are con-tinuing.
;
r 1 ~937~
Experiment III
The eEfect o:E NCNU was tested against Yancey's lymphocytic leukemia (YLL) which had been implanted sub-cutaneously (sc) two days before injection of the drug. The single injection of 0.1 ml of a solution of one spleen of a YLL bearing mouse homogenized in 10 ml Locke's Solution was given ei-ther intraperi-toneally or subcutaneously. Table III presents the increase in median li~e span of test animals over control animals.
TABLE III
Effects of Single-Dose Treatment with NCNU Against Two-Day Yancey ~ ~ kemia Dose Route of Injection % ILS
2.0 mg/mouse ip 264 +
1.0 mg/mouse ip 64.3 0.5 mg/mouse ip 14.3 25 mg/kg ip 13.3 50 mg/kg ip 60.0 75 mg/kg ip 66.6 2.0 mg/mouse sc 78.0 1.0 mg/mouse sc 64.3 0.5 mg/mouse sc 35.7 25 mg/kg sc 6.6 50 mg/kg sc 60.0 75 mg/kg sc 73.3 1.0 mg/mouse ip 33.3 0.5 mg/mouse ip 6.7 1.0 mg/mouse sc 20.0 0.5 mg/mouse sc 13.3 The plus sign indicates that the animals have not yet all died and -the experiments are continuing.
1 17g3~
E:xpe~iment LV
The study oE Experiment III was conducted with NCNU treatment beginniny at 2 or 7 days after implantation of YLI. tumors. NCNU injec-tion was ip or sc on a schedule of one time per week for 4 weeks, twice per week for 4 weeks, or a single dose, Results are provided in Table IV.
TABLE IV
Effects of NCNU Against Yancey's Lymphocytic Leukemia Day After Implantation Treatment Route of Injection Dose_Was Begun In~ectlon Schedule % ILS
1.0 mg/mouse 7ip once 66.6 0.5 mg/mouse 7ip once 6.7 1.0 mg/mouse 7sc once 66.6 0.5 mg/mouse 7sc once 6.7 2.0 mg/mouse 2ip lx/wk ~or 4 wks 14.3 1.0 my/mouse 2 ip " 178.6 0.5 mg/mouse 2 ip " 28.6 75 mg/kg 2 ip " 100 +
50 mg/kg 2 ip i, 100 +
25 my/kg 2 ip " 100 +
2.0 mg/mouse 2 sc " 264 +
1.0 mg/mouse 2 sc " 207.1 +
0.5 mg/mouse 2 sc " 114.3 +
75 mg/ky 2 sc " 100 +
50 mg/kg 2 sc " 100 +
25 mg/kg 2 sc " 100 +
75 mg/kg 2 ip 2x/wk Eor 4 wks 66.6 50 mg/kg 2 ip " lO0 +
25 mg/kg 2 ip " lO0 +
75 mg/kg 2 sc " 0 50 mg/kg 2 sc " lO0 -~
25 mg/kg 2 sc " 100 +
The plus sign indicates that the animals have no-t yet all died and the experiments are continuing.
~-I ~L 793~
Experiment_V
Toxicity s-tudies were conducted by injecting a single dose of NCNU ip. Survival data is set forth in Table V.
TABI.E V
Toxicity of NCNU in CDFl Normal Mice Dose Dea-ths (%) 1.0 mg/mouse 0 2.0 mg/mouse 60 at day 13, others survived 104.0 mg/mouse 100 at day 10 8.0 mg/mouse 100 at day 8 16.0 mg/mouse 100 at day 4 20.0 mg/mouse lQ0 at day 1 32.0 mg/mouse 100 at day 1 100 mg/kg 100 at day 13 150 mg/kg 100 at day 11 200 mg/kcJ 100 at day 9 225 mg/kg 100 at day 9 250 mg/kg 100 at day 8 500 mc3/kg 100 at day 5 750 mg/kg 100 a-t day 2 1000 mg/kg 100 at day 1 PHARMACEUTICAL COMPOSITIONS
The compounds of this invention can be employed in useful pharmaceutical compositions in such dosage forms as tablets, capsules, powder packets, liquid solutions, suspen-sions or elixirs for oral administration; liquid for parenteral use, and in certaln cases, suspensions for parenteral use.
In such compositions, the active ingredient will ordinarily be present in an amount of at least 0.5~ by weight based on the total weight of the composition and not more than 95~ by weight.
Besides the active ingredient compound of this invention, the antitumor composition can contain a solid or liquid non-toxic pharmaceutical carrier for the active ~ ,.
~ 17937~
in~redient.
The capsules, tablets, and powders will generally constitute from about 1 to about 95~ and preferably from about 5 to 90~ by weight of active ingredient. These dosage forms preferably contain from about 5 milliqrams to about 500 milligrams of active ingredient, with about 7 milligrams to about 250 milligrams most preerred.
The pharmaceutical carrier can be a sterile liquid such as water, or a suitable oil, including those of petrol, animal, or ve~etable oil of synthetic origin, for example, peanut oil, soybean oil, mineral oil, sesame oil, and the like. In general, water, saline, aqueous dex-trose (glucose) and related sugar solutions and glycols such as propy:lene glycol and polyethylene glycols are preferred liquicl carriers particularly for injectible solutions. Sterile in~ectible solutions will ordinarily con-tain from about 0.5 -to about 25~ and preferably about 1 to about 10~ by weight of the active ingredient.
Oral administration can be in a suitable suspension or syrup, in which the active ingredient ordinarily will constitute from about 0.7 to about 10~ and preferably about 1 to about 5% by weight. The pharmaceutical carrier in the composition can be an aqueous vehicle such as an aromatic water, a syrup, or a pharmaceutical mucilage.
Suitable pharmaceutica~ carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin, a well-known reference text in this field.
The following examples will further illustrate the preparation of pharmaceutical compositions of the invention.
1 ~9372 EXAMPL~ A
A large number of unit capsules were prepared by filling standard two-piece hard gelatin capsules each with 250 milligrams of powdered 1-neopentyl-3-(2-chloro~thyl)-3-nitrosourea, 110 milligrams of lactose, 32 milligrams of talc, and 8 milligrams stearate.
EXAMPLE B
A mixture of l-neopentyl-3-(2-fluoroethyl)-3-nitrosourea in soybean oil was prepared and injected by meansof a positive displacement pump into gelatin to form soEt gelatin capsules containing 35 milligrams of the active ingredient. The capsules were washed in petrole-lm ether and dried~
EXAMPLE C
A large number of tablets were prepared by conventional procedures so tha-t the dosage unit was 100 milligrams of active ingredient, 7 milligrams of ethyl cellulose, 0.2 milligrams of colloidal silicon dioxide, 7 milligrams of magnesium stearate, 11 milligrams of microcrystalline cellu-lose, 11 milligrams of cornstarch and 98.8 milligrams oE lac-tose. Appropriate coatings may be applied to increase palata-bility or delay absorption~
EXAMPLE D
A parenteral composition suitable for administration by injection was prepared by stirring 1.5% by weigh-t of l-isopentyl-3-(2-chloroethyl)-3-nitrosourea in 10% by volume propylene glycol and water. The solution was sterili~ed by 1 ~7~7~
filtration.
EXAMPL_ _ An aqueous suspension was prepared for oral adminis-tration so that each 5 milliliters contained 50 milligrams of finely divided l-neohexyl-3-(2-chloroethyl)-3-nitrosourea, 500 milligrams of acacia, S milligrams o-f sodium benzoate, 1.0 gram of sorbi-tol solution, U.S.P., 5 milligrams of sodium saccharin, and ~.025 milliliters of vanilla tincture.
EXAMPLE F
A parenteral composition suitable for adminis-tration by injec-tion was prepared by dissolvjng 1% by weigllt of l-neopen-tyl-3-(2-chloroethyl)-3-nitrosourea in sodium chloride injection U.S.P. XV and adjusting the pH of the solu-tion to between 6 and 7. The solution was sterilized by filtration.
A wide variety of compositions can be prepared by substituting other compounds embraced by this invention for the specific compounds named in Examples A-F above and substituting other suitable pharmaceutical carriers described in "Remington's Pharmaceutical Sciences".
The compounds of this invention can be administered in the treatment of any of the various forms of cancer by any means that effects contact of -the active ingredient compound with the site of action in the body of a warm-blooded animal. For example, administration can be parenteral, i.e., subcutaneous, intravenous, intramuscular, or intra-peritoneal; alternatively or concurrently, administration can be by the oral route.
al793~
For the purpose of this disclosure, a warm-blooded animal is a member of the animal kingdom possessed of a homeostatic mechanism and includes mammals ancl birds.
The dosage administered is dependent on the age, health, and wei~ht of the recipient, the extent of disease, kind of concuxrent treatment, frequency of treatment and the effect desired. Usually, a daily dosage of active ingredient compound can be from about 0.1 to lS0 milligrams per kilogram of body weight. Ordinarily, from 2.0 to 75, and preferably 10 to 50 milligrams per day administered in one or more doses daily is effective to obtain the desired results.
HUMA STUDIES
Patients having advanced stages of various forms oE
cancer were treated by subcutaneous injection of two 25 mg/kg doses of NCNU in water or by intravenous administration of 1 milligram NCNU/ml 0.9% saline to provide a total daily dose of 50 mg/kg; a full clinical examination was carried out prior to and after administration. Tumor grow-th was measured where possible by palpitation, x-rays and photo-graphy.
Following treatment patients showed marked clinical improvement within several days. Inflammation gradually subsided and tumor size frequently decreased.
The following types of cancer in addition to others, may be treated with compounds of the invention: tl) undif-ferentiated carcinoma of the (R) ]cidney with metastases, (2) adenocarcinoma of the colon with liver metastases, (3) intraduct carcinoma of the breast (stage IV) with bone metastases, (4) recurrent melanoma, (5) adenocarinoma of the .~ ,'~
7 ~793~2 breast wlth brain metastases and (6) squamous cell carcinoma of the lung.
The above clinical s-tudies establish that the l-branched-alkyl-3-(2-haloethyl)-3-nitrosourea compounds oE
the invention are useful in the treatment of various forms of cancer. Continuous intravenous administration inhibits tumor activi-ty and frequently leads to a general remission of the disease.
The mode of action of the compounds of the invention is, at this point, unclear. However, the empirical observation that cells stop prolifera-tion when exposed to these compounds is sufficient to warrant their use in thq treatment oE such serious, heretofore untreatable, and often fatal diseases, such as cancer.
. ,,, .~
l 1~937,'~
SUPPLEMENTARY DISCLOSURE
In the principal disclosure, there are described certain specific l-branched-alkyl-3-(2-haloethyl)-3-nitroso-ureas havilg antitumor activity and the preparation thereof.
It has now been found that a wider group of compounds than the specific ones disclosed in the principal disclosure have antitun,or activity.
Compounds in accordance with the following criteria have been found to have antitumor activity:
1. The compounds should contain an alkyl isocyanate component of a nitrosourea. It is known that the nitrosourea, as in or example BCNU and CCNU, dissociates ln vivo and in v _ o to yield the isocyanate and diazotic acid ractions. The isocyanate thus produced then acts as the "active site" inhi-bitor for the transglutaminase as discussed in the main dis-closure.
2. At present it is believed that the diazotic acid component should be the same as that for BCNU and CCNU.
3. The compounds should contain an alkyl group of preferably 3 to 8 carbon atoms attached to the isocyanate group.
~roups with more than 10 carbon atoms present solubility pro-blems while methyl and ethyl isocyanate would generally be too toxic (carcinogenic).
According to an aspect of this invention there is provided a process for preparing a compound of the general formula:
Il R- NH- C- N- CH2- CH2- Hal (A) N=O
wherein R is selected from the group consisting of neopentyl, neohexyl, isopentyl and isobutyl and Hal is selected , I
" .
~ ~7937~
from -the group consisting oE chlorine and fluorine, the process comprisiny nitrosolating a compound of the general formula:
R- NH- C -NH- CH2- CH2- Hal with nitrous aci.d.
Compounds having the formula (A) have an'itumor activ-itY and are novel. In accordance with another aspect of the invention such compounds are provided whenever produced by the process aspect of the invention, or by an obvious chemical equivalent thereof.
The following compounds of the invention were synthesized as described in the Experimental section:
o R- NH- C - N- CH2 CH2 Hal N=O
,)o V, R = Neopentyl VI, R = Neohexyl VII, R = Isopentyl VIII, R = Isobutyl Hal = Cl or F
~ 179~72 Chemical studies revealed that the neopentyl and neohexyl isocyanates are remarkahly stable in water-acetone (1:3) at 57 C without substantial amounts being hydroly~ed even after a three-day period at pH 6Ø Both have half-lives of greater than 30 minutes at physiological pH and tempera-ture.
Thus, the branched alkyl groups of the compounds of the invention were selected using the criterion that they should be substrates for, and thus be selective inhibitors of, transglutaminase. As noted above, the work oE Montgomery discloses a single l-branched-alkyl-3-~2-chloroethyl)-3 nitrosourea, namely l-(l-me-thyl-hexyl)-3-(2-chloroethyl)-3-ni-trosourea (IX):
cl~3cf~2c~2cH2c~l2- fH~ NH- C- N- CH2CH2~ Cl (IX) While this compound is a l-branched-alkyl-3-(2-chloroethyl)-3-nitrosourea, it does not fulfill the steric criteria outlined above for optimal inhibitory activi-ty.
It is not desired to limit the invention by the theoretical considerations presented herein, and the above discussion is included merely for purposes of background discussion.
EXPERIMENTAL SECTION
Melting points were determined using a Thomas Hoover capillary melting point appara-tus and are uncorrected.
InErarecl (IR) spectra were obtainecl using a Perkin Elmer 397 spectrophotometer, and NMR (nuclear magnetic resonance) spectra were taken on a Br~ker ~P80DS system with tetramethyl-silane as an internal standard. Elemental analyses were carried out by Calbraith Laboratories, Knoxville, Tennessee.
Butyl acetyl chloride and 3,3 dime-thyl-l-butallol were obtained from Aldrich Chemical Co. and were used wlthout further purification as a result of sa-tisfactory NMR analysis.
1-Neopentyl-3-(2-Chloroethyl~ Urea. Neopentylamine (8.7 g, 0.1 mol) was dissolved in 50 ml of anhydrous diethyl ether and cooled to 5C. 2-Chloroethyl isocyanate (10.5 g, ().1 mol) dissolved in an additional 50 ml of ether was aclded over :30 minutes while maintaining a tempera-ture of less than 1() C.
Stirring continued for an addi-tional hour, ancl ~he cold mixture was filtered and washecl with chilled ether. The compound was dried in a desiccator over sodium hydroxide overnight giving 15.4 g (80%) as a whi-te powder, MP (meltiny point) 90-1C (decomposes). Elemental analysis showed the following:
Calculated Found Carbon 49.97% 49.87%
Hydrogen 8.87% 8.89%
Nitroyen 14.52% 14.54%
Chlorine 18.47~ 18.40%
IR analysis showed bands at 1630/cm (C=O) and 1535/cm (N-C=O). NMR showed a singlet (9H) at 0.8 ppm and a mutliplet (6H) at 3.4 ppm.
1 1 7~372 l-Neopentyl-3-~2-Chloroethyl)-3-Nitr~sourea (V). The entire _ __ _ _ _ yield of l-neopentyl-3-(2-chloroethyl~ urea (0.08 mol) was dissolved in 120 ml of concentrated HCl:ethanol, 2:1 at 5 C
in a 500 ml round bo-ttom flask equipped with magnetic stirrer. Sodium nitrite (5.5 g, 0.08 mol) was dissolved in 30 ml of water and added to the solution over a ten-minute period. Stirring continued for 2 hrs., and the yellow, crystalline precipita-te was filtered and washed with five 100 ml portions of chilled distilled water. The product was dried in vacuo for 18 hrs. giving 15 g (84%~ which melted with decomposition at 52-3C. IR analysis showed peaks at 1730/cm (C=O~ and 1520/cm (C-N-H). NMR showed a singlet (9EI) at 1 ppm, a doublet (2H, J = 6.5 Hz) at 3.3 ppm, a triplet (2H, J -- 6.5 llz) at 3.6 ppm, and a triple-t (2H, J = 6.5 Hz) at 4.2 ppm.
1-Neohexyl-3 ~ . A 5 g quantity of 3,3-dimethyl butylamine (0.5 mol) was dissolved in 30 ml of anhydrous diethyl ether and stirred on an ice bath.
2-Chloroethyl isocyanate (5.25 g, 0.5 mol) dissolved in 15 ml of ether was added maintaining a temperature of 10 C or less, and stirring continued for 2 hrs. Fil-tering the product and washing with four 5 ml portions of chilled ether afforded 6.2 g (60%) which melted at 84C (decomposes). IR
analysis showed peaks at 1625/cm (C-O) and ]580/cm (N-C=O).
NMR: singlet (9H) at 0.9 ppm, multiplet (2H) at 1.3 ppm, multiplet (2H) at 3.2 ppm, multiplet (4H) at 3.5 ppm, singlet (lH) at 5.5 ppm, and singlet ~lH) at 5.7 ppm.
`1~
1 ~79372 _Neohexyl-3-(2-Chloroethyl)-3--Nitrosourea (VI). A 2.07 g (10 mmol) quantity of 1-neohexyl-3-~2-chloroethyl) urea was dissolved in 15 ml of concentrated HCl:ethanol, 2:1, at 10 C, and 690 mg (10 mmol) sodium nitrite dissolved in 3 ml oE water was added. Stirring at 0.5C continued Eor 1.5 hrs.
and the precipita-te was washed with four 25 ml portions of distilled water. After drying in vacuo overnight, 1.7 g (74%) of the product was obtained which meltecl at 43.0-43.5C (decomposes). IR analysis showed peaks at 17C5/cm (C=O) and 1525/cm (C-N=O). NMR: singlet (9H) at 0.9 ppm, mul-tiplet (2H) at 1.3 ppm, symmetrical multiplet (6H) at 3.8 ppm. No evidence of isomeric ma-terial was detected.
l-Isopentyl-3-(2-Chloroethyl) Urea. Isopentylamine (8.7 c3, 0.1 mol) was dissolved in 100 ml of anhydrous ether and cooled to less -than 10C. 2-Chloroethyl isocyana-te (10.5 cJ, 0.1 mol) was dissolved in 20 ml of ether and added to -the rapidly stirring reaction mixture at less than 10C. Stirring was continued for 1 hr. longer and the precipitate was filtered and washed with four 20 ml portions of chilled ether.
After drying in vacuo overnight, 16.5 g (85~) of product was obtained as a white powder, MP 58-9C. IR analysis showed peaks at 1620/cm (C=O) and 1575/cm (N-C=O). NMR showed a doublet (6H, J = 7 Hz) at 0.9 ppm, a triplet (2H,J = 7 Hz) at 1.4 ppm, a multiplet (lH) at 1.8 ppm, a multiplet (lH) at 3.2 ppm, a multiplet (4H) at 3.6 ppm, a singlet (lH) at 5 7 ppm, and a singlet (lH) at 6.0 ppm.
l-Isopentyl-3-(2-Chloroethyl)-3-Nitrosourea (VII). A 1.92 g (10 mmol) quantity of 1-isopentyl-3-(2-chloroethyl~ urea ~.
was dissolved in 15 ml o~ HCl:ethonal, 2:1, and cooled to 5C. Sodium nitrite (690 mg, 10 mrnol) dissolved in 3 ml of water was added in portions with stirring, after which stirring was continued for an additional 2 hrs. The mixture was filtered and 50 ml of water was added. Extracting with two 20 ml portions of ethyl acetate Eollowed by evaporation of the solvent afforded the product as an oil which did not solidify on standing. Similar resul-ts were obtained using 98% formic acid as the solvent. IR analysis showed peaks at 1705/cm (C=O) and 1525/cm (N-C=O~. NMR analysis showed a doublet (6H, J = 7 Hz) at 0.9 ppm, a triplet (2H, J = 7 Hz) at 1.4 ppm, a multiplet (lH) at 1.8 ppm, a multiple-t (6H) at 3.8 ppm, and a singlet (lH) a-t 7.4 ppm.
l-Isobut~l-3-(2-Chlor ~ ~rea. Isobu-tylamine ~7.3 ~, 0.1 mol) was dissolved in 20 ml of die-thyl ether and cooled to less than 5 C. Chloroethyl isocyana-te (10.5 9, 0.1 mol) dissolved in 15 ml of ether was added maintaining a tempera-ture between 0 and 5 C with vigorous stirring. Stirring was continued for an additional 2 hrs. the mixture was cooled to -5C, and the product (4.1 g, 46~) was filtered and dried in vacuo for 18 hrs. over KOH, MP 79.5 C (decomposes).
IR analysis showed peaks at 1630/cm (C=O) and 1585/cm (N-C=O).
NMR: Doublet at 0.9 ppm (J = 6.4 Hz), multiplet (lH) a-t 2.1 ppm, quartet (2H) at 2.9 ppm (J = 6.4 Hz), multiplet (4H) at 3.5 ppm.
l-Isobutyl-3-(2-Chloroethyl)-3-Nitrosourea (VIII). A 2 g (11.2 mmol) quantity of 1-isobutyl-3-(2-chloroethyl) urea was dissolved in 25 ml of concentrated HCl:e-thanol, 2:1, .
.-1 1~9372 and cooled to S C. A solution of 773 mg ~11.2 mmol) o~ sodium nitrite in 5 ml of water was added in portions and the mixture was stirred at this temperature for 2 hrs. The crystalline yellow solid was filtered and dried in vacuo overnight giving 1.6 g (70~) oE the product, MP 51C
(decomposes). IR analysis showed peaks at 1705~cm (C=O) and 1525/cm (C-N=O). NMR: Doublet (6H, J = 6.8 Hz) at 0.9 ppm, multiplet (1~l) at 2.0 ppm, multiplet (6H) at 3.7 ppm.
1-Branched-alkyl-3-(2-fluoroethyl)-3-nitrosoureas. Syntheses corresponding to those described above may be performed using the 2-fluoroethyl compounds to produce the l-branched-alkyl-3-(2-fluoroethyl)-3-nitrosoureas.
CLINICAL STUDIES
Exper1ment I
A single dose of l-neopentyl-3-(~-chloroethyl)-3-nitrosourea (NCNU) was injected intraperitoneally (ip) in CDF1 mice which had been implanted ip two days earlier with approximately 10 x 105 murine leukemia L1210 tumor cells.
The NCNU was dissoIved in Emulphor EL-620 (polyoxyethylated;
GAF Corporation, New York, N.Y.) and raised to the desired volume with 0.85~ sodium chloride. The increase in median lifespan (ILS) of the test animals above control (untreated) animals is presented in Table I.
* A Trade Mark TABLE I
Effects of Single-Dose Treatment with NCNU Against _ 'l'wo-Day Murine Leukemia L1210 Dose (mg/kg) '~ ILS
_ 100 275 ~
275 +
37.S
Experiment II
The s-tudy of Experiment I was conducted using approximately 5 x 105 murine leukemia P388 tumor c~lls (0.1 ml of a 1:100 dilu-tion). Results are presented in Table II.
TABLE II
.
Effects of Single-Dose Treatment with NCNU Against Two-Day Murine Leukemia P388 Dose (mg/Mouse) % ILS
-2.0 483 +
1.0 91.7 0.5 41.5 , The plus sign indicates that the animals have not yet all died and the experiments are con-tinuing.
;
r 1 ~937~
Experiment III
The eEfect o:E NCNU was tested against Yancey's lymphocytic leukemia (YLL) which had been implanted sub-cutaneously (sc) two days before injection of the drug. The single injection of 0.1 ml of a solution of one spleen of a YLL bearing mouse homogenized in 10 ml Locke's Solution was given ei-ther intraperi-toneally or subcutaneously. Table III presents the increase in median li~e span of test animals over control animals.
TABLE III
Effects of Single-Dose Treatment with NCNU Against Two-Day Yancey ~ ~ kemia Dose Route of Injection % ILS
2.0 mg/mouse ip 264 +
1.0 mg/mouse ip 64.3 0.5 mg/mouse ip 14.3 25 mg/kg ip 13.3 50 mg/kg ip 60.0 75 mg/kg ip 66.6 2.0 mg/mouse sc 78.0 1.0 mg/mouse sc 64.3 0.5 mg/mouse sc 35.7 25 mg/kg sc 6.6 50 mg/kg sc 60.0 75 mg/kg sc 73.3 1.0 mg/mouse ip 33.3 0.5 mg/mouse ip 6.7 1.0 mg/mouse sc 20.0 0.5 mg/mouse sc 13.3 The plus sign indicates that the animals have not yet all died and -the experiments are continuing.
1 17g3~
E:xpe~iment LV
The study oE Experiment III was conducted with NCNU treatment beginniny at 2 or 7 days after implantation of YLI. tumors. NCNU injec-tion was ip or sc on a schedule of one time per week for 4 weeks, twice per week for 4 weeks, or a single dose, Results are provided in Table IV.
TABLE IV
Effects of NCNU Against Yancey's Lymphocytic Leukemia Day After Implantation Treatment Route of Injection Dose_Was Begun In~ectlon Schedule % ILS
1.0 mg/mouse 7ip once 66.6 0.5 mg/mouse 7ip once 6.7 1.0 mg/mouse 7sc once 66.6 0.5 mg/mouse 7sc once 6.7 2.0 mg/mouse 2ip lx/wk ~or 4 wks 14.3 1.0 my/mouse 2 ip " 178.6 0.5 mg/mouse 2 ip " 28.6 75 mg/kg 2 ip " 100 +
50 mg/kg 2 ip i, 100 +
25 my/kg 2 ip " 100 +
2.0 mg/mouse 2 sc " 264 +
1.0 mg/mouse 2 sc " 207.1 +
0.5 mg/mouse 2 sc " 114.3 +
75 mg/ky 2 sc " 100 +
50 mg/kg 2 sc " 100 +
25 mg/kg 2 sc " 100 +
75 mg/kg 2 ip 2x/wk Eor 4 wks 66.6 50 mg/kg 2 ip " lO0 +
25 mg/kg 2 ip " lO0 +
75 mg/kg 2 sc " 0 50 mg/kg 2 sc " lO0 -~
25 mg/kg 2 sc " 100 +
The plus sign indicates that the animals have no-t yet all died and the experiments are continuing.
~-I ~L 793~
Experiment_V
Toxicity s-tudies were conducted by injecting a single dose of NCNU ip. Survival data is set forth in Table V.
TABI.E V
Toxicity of NCNU in CDFl Normal Mice Dose Dea-ths (%) 1.0 mg/mouse 0 2.0 mg/mouse 60 at day 13, others survived 104.0 mg/mouse 100 at day 10 8.0 mg/mouse 100 at day 8 16.0 mg/mouse 100 at day 4 20.0 mg/mouse lQ0 at day 1 32.0 mg/mouse 100 at day 1 100 mg/kg 100 at day 13 150 mg/kg 100 at day 11 200 mg/kcJ 100 at day 9 225 mg/kg 100 at day 9 250 mg/kg 100 at day 8 500 mc3/kg 100 at day 5 750 mg/kg 100 a-t day 2 1000 mg/kg 100 at day 1 PHARMACEUTICAL COMPOSITIONS
The compounds of this invention can be employed in useful pharmaceutical compositions in such dosage forms as tablets, capsules, powder packets, liquid solutions, suspen-sions or elixirs for oral administration; liquid for parenteral use, and in certaln cases, suspensions for parenteral use.
In such compositions, the active ingredient will ordinarily be present in an amount of at least 0.5~ by weight based on the total weight of the composition and not more than 95~ by weight.
Besides the active ingredient compound of this invention, the antitumor composition can contain a solid or liquid non-toxic pharmaceutical carrier for the active ~ ,.
~ 17937~
in~redient.
The capsules, tablets, and powders will generally constitute from about 1 to about 95~ and preferably from about 5 to 90~ by weight of active ingredient. These dosage forms preferably contain from about 5 milliqrams to about 500 milligrams of active ingredient, with about 7 milligrams to about 250 milligrams most preerred.
The pharmaceutical carrier can be a sterile liquid such as water, or a suitable oil, including those of petrol, animal, or ve~etable oil of synthetic origin, for example, peanut oil, soybean oil, mineral oil, sesame oil, and the like. In general, water, saline, aqueous dex-trose (glucose) and related sugar solutions and glycols such as propy:lene glycol and polyethylene glycols are preferred liquicl carriers particularly for injectible solutions. Sterile in~ectible solutions will ordinarily con-tain from about 0.5 -to about 25~ and preferably about 1 to about 10~ by weight of the active ingredient.
Oral administration can be in a suitable suspension or syrup, in which the active ingredient ordinarily will constitute from about 0.7 to about 10~ and preferably about 1 to about 5% by weight. The pharmaceutical carrier in the composition can be an aqueous vehicle such as an aromatic water, a syrup, or a pharmaceutical mucilage.
Suitable pharmaceutica~ carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin, a well-known reference text in this field.
The following examples will further illustrate the preparation of pharmaceutical compositions of the invention.
1 ~9372 EXAMPL~ A
A large number of unit capsules were prepared by filling standard two-piece hard gelatin capsules each with 250 milligrams of powdered 1-neopentyl-3-(2-chloro~thyl)-3-nitrosourea, 110 milligrams of lactose, 32 milligrams of talc, and 8 milligrams stearate.
EXAMPLE B
A mixture of l-neopentyl-3-(2-fluoroethyl)-3-nitrosourea in soybean oil was prepared and injected by meansof a positive displacement pump into gelatin to form soEt gelatin capsules containing 35 milligrams of the active ingredient. The capsules were washed in petrole-lm ether and dried~
EXAMPLE C
A large number of tablets were prepared by conventional procedures so tha-t the dosage unit was 100 milligrams of active ingredient, 7 milligrams of ethyl cellulose, 0.2 milligrams of colloidal silicon dioxide, 7 milligrams of magnesium stearate, 11 milligrams of microcrystalline cellu-lose, 11 milligrams of cornstarch and 98.8 milligrams oE lac-tose. Appropriate coatings may be applied to increase palata-bility or delay absorption~
EXAMPLE D
A parenteral composition suitable for administration by injection was prepared by stirring 1.5% by weigh-t of l-isopentyl-3-(2-chloroethyl)-3-nitrosourea in 10% by volume propylene glycol and water. The solution was sterili~ed by 1 ~7~7~
filtration.
EXAMPL_ _ An aqueous suspension was prepared for oral adminis-tration so that each 5 milliliters contained 50 milligrams of finely divided l-neohexyl-3-(2-chloroethyl)-3-nitrosourea, 500 milligrams of acacia, S milligrams o-f sodium benzoate, 1.0 gram of sorbi-tol solution, U.S.P., 5 milligrams of sodium saccharin, and ~.025 milliliters of vanilla tincture.
EXAMPLE F
A parenteral composition suitable for adminis-tration by injec-tion was prepared by dissolvjng 1% by weigllt of l-neopen-tyl-3-(2-chloroethyl)-3-nitrosourea in sodium chloride injection U.S.P. XV and adjusting the pH of the solu-tion to between 6 and 7. The solution was sterilized by filtration.
A wide variety of compositions can be prepared by substituting other compounds embraced by this invention for the specific compounds named in Examples A-F above and substituting other suitable pharmaceutical carriers described in "Remington's Pharmaceutical Sciences".
The compounds of this invention can be administered in the treatment of any of the various forms of cancer by any means that effects contact of -the active ingredient compound with the site of action in the body of a warm-blooded animal. For example, administration can be parenteral, i.e., subcutaneous, intravenous, intramuscular, or intra-peritoneal; alternatively or concurrently, administration can be by the oral route.
al793~
For the purpose of this disclosure, a warm-blooded animal is a member of the animal kingdom possessed of a homeostatic mechanism and includes mammals ancl birds.
The dosage administered is dependent on the age, health, and wei~ht of the recipient, the extent of disease, kind of concuxrent treatment, frequency of treatment and the effect desired. Usually, a daily dosage of active ingredient compound can be from about 0.1 to lS0 milligrams per kilogram of body weight. Ordinarily, from 2.0 to 75, and preferably 10 to 50 milligrams per day administered in one or more doses daily is effective to obtain the desired results.
HUMA STUDIES
Patients having advanced stages of various forms oE
cancer were treated by subcutaneous injection of two 25 mg/kg doses of NCNU in water or by intravenous administration of 1 milligram NCNU/ml 0.9% saline to provide a total daily dose of 50 mg/kg; a full clinical examination was carried out prior to and after administration. Tumor grow-th was measured where possible by palpitation, x-rays and photo-graphy.
Following treatment patients showed marked clinical improvement within several days. Inflammation gradually subsided and tumor size frequently decreased.
The following types of cancer in addition to others, may be treated with compounds of the invention: tl) undif-ferentiated carcinoma of the (R) ]cidney with metastases, (2) adenocarcinoma of the colon with liver metastases, (3) intraduct carcinoma of the breast (stage IV) with bone metastases, (4) recurrent melanoma, (5) adenocarinoma of the .~ ,'~
7 ~793~2 breast wlth brain metastases and (6) squamous cell carcinoma of the lung.
The above clinical s-tudies establish that the l-branched-alkyl-3-(2-haloethyl)-3-nitrosourea compounds oE
the invention are useful in the treatment of various forms of cancer. Continuous intravenous administration inhibits tumor activi-ty and frequently leads to a general remission of the disease.
The mode of action of the compounds of the invention is, at this point, unclear. However, the empirical observation that cells stop prolifera-tion when exposed to these compounds is sufficient to warrant their use in thq treatment oE such serious, heretofore untreatable, and often fatal diseases, such as cancer.
. ,,, .~
l 1~937,'~
SUPPLEMENTARY DISCLOSURE
In the principal disclosure, there are described certain specific l-branched-alkyl-3-(2-haloethyl)-3-nitroso-ureas havilg antitumor activity and the preparation thereof.
It has now been found that a wider group of compounds than the specific ones disclosed in the principal disclosure have antitun,or activity.
Compounds in accordance with the following criteria have been found to have antitumor activity:
1. The compounds should contain an alkyl isocyanate component of a nitrosourea. It is known that the nitrosourea, as in or example BCNU and CCNU, dissociates ln vivo and in v _ o to yield the isocyanate and diazotic acid ractions. The isocyanate thus produced then acts as the "active site" inhi-bitor for the transglutaminase as discussed in the main dis-closure.
2. At present it is believed that the diazotic acid component should be the same as that for BCNU and CCNU.
3. The compounds should contain an alkyl group of preferably 3 to 8 carbon atoms attached to the isocyanate group.
~roups with more than 10 carbon atoms present solubility pro-blems while methyl and ethyl isocyanate would generally be too toxic (carcinogenic).
4. To be effective, the Cl of the above noted alkyl group should be primary, i.e. with no branching or substituents, since it is '-nown that such compounds, with tertiary and probably also with secondary, Cls would be ineffective becuase of stearic hindrances which would preclude access by the alkyl isocyanate to the active site of the enzyme. Preferably, the alkyl group should be branched, e.~. with method groups at the C2 or C3 posi-tions. However, C4 substituted or branched alkyls are believed likely to be less effective inhibitors because of steric _ ~, _ ~ 1 ~93~72 hindrances. In summary it can therefore be said that branch-ing on the first carbon adjacent to the isocyanate group is in-effective, that on the second carbon, highly effective and that decreasing activity would result as the branching moves out along the chain.
5. In light of the substrate specificity of trans-glutaminase the above notea alkyl group should preferably conform as closely as practicable to a glutamine residue. Howe~er, it has been demonstrated that isocyanate containing an alkyl chain 8 carbons long is still a good inhibitor of transglutaminase.
From the above criteria compounds of general formula X have antitumor activity by lnhibiting transglutaminase.
R NH ~ I--CH2 CH2 al X
NO
wherein ~ is an alkyl group of 3 to 8 carbon atoms with no branch-ing on the Cl and Hal is chlorine or fluorine. Those compounds form one aspect of the invention of this supplementary disclo-sure, whenever prepared by the process aspect hereof defined below.
A preferred embodiment of compounds of formula X
embodies branching on the C2 or C3 of the R group; and a further preferred embodiment of X is ~here the R group sterically conforms to a glutamine residue.
Compounds of the formula X are prepared, in accordance with another aspect of the invention of this supplementary disclosure, by nitrosolating a compound of the formula XI with nitrous acid O
R - NH - C - HN - CH2 - CH~ - Hal XI
~ ~ -- `2 ;L --~J
From the above criteria compounds of general formula X have antitumor activity by lnhibiting transglutaminase.
R NH ~ I--CH2 CH2 al X
NO
wherein ~ is an alkyl group of 3 to 8 carbon atoms with no branch-ing on the Cl and Hal is chlorine or fluorine. Those compounds form one aspect of the invention of this supplementary disclo-sure, whenever prepared by the process aspect hereof defined below.
A preferred embodiment of compounds of formula X
embodies branching on the C2 or C3 of the R group; and a further preferred embodiment of X is ~here the R group sterically conforms to a glutamine residue.
Compounds of the formula X are prepared, in accordance with another aspect of the invention of this supplementary disclosure, by nitrosolating a compound of the formula XI with nitrous acid O
R - NH - C - HN - CH2 - CH~ - Hal XI
~ ~ -- `2 ;L --~J
Claims (18)
1. A process for preparing a compound of the general formula:
wherein R is selected from the group consisting of neopentyl, neohexyl, isopentyl and isobutyl and Hal is selected from the group consisting of chlorine and fluorine, said process com-prising; nitrosolating a compound of the general formula:
with nitrous acid.
wherein R is selected from the group consisting of neopentyl, neohexyl, isopentyl and isobutyl and Hal is selected from the group consisting of chlorine and fluorine, said process com-prising; nitrosolating a compound of the general formula:
with nitrous acid.
2. A process as defined in claim 1, wherein R is neo-pentyl and Hal is chlorine.
3. A process as defined in claim 1, wherein R is neo-hexyl and Hal is chlorine.
4. A process as defined in claim 1, wherein R is iso-pentyl and Hal is chlorine.
5. A process as defined in claim 1, wherein R is iso-butyl and Hal is chlorine.
6. A compound of the general formula:
wherein R is selected from the group consisting of neopentyl, neohexyl, isopentyl and isobutyl and Hal is selected from chlorine and fluorine, whenever prepared by the process of claim 1, or by an obvious chemical equivalent thereof.
wherein R is selected from the group consisting of neopentyl, neohexyl, isopentyl and isobutyl and Hal is selected from chlorine and fluorine, whenever prepared by the process of claim 1, or by an obvious chemical equivalent thereof.
7. 1-neopentyl-3-(2-chloroethyl)-3-nitrosourea, whenever prepared by the process of claim 2, or by an obvious chemical equivaleht thereof.
8. 1-neohexyl-3-(2-chloroethyl)-3-nitrosourea, whenever prepared by the process of claim 3, or by an obvious chemical equivalent thereof.
9. 1-isopentyl-3-(2-chloroethyl)-3-nitrosourea, whenever prepared by the process of claim 4, or by an obvious chemical equivalent thereof.
10. 1-isobutyl-3-(2-chloroethyl)-3-nitrosourea, whenever prepared by the process of claim 5, or by an obvious chemical equivalent thereof.
Claims Supported By The Supplementary Disclosure
Claims Supported By The Supplementary Disclosure
11. A process for preparing a compound of the general formula:
wherein R is an alkyl group of 3 to 8 carbon atoms with no branching at the Cl atom and Hal is selected from the group consisting of chlorine and fluorine, said process comprising nitrosolating a compound of the general formula:
with nitrous acid.
wherein R is an alkyl group of 3 to 8 carbon atoms with no branching at the Cl atom and Hal is selected from the group consisting of chlorine and fluorine, said process comprising nitrosolating a compound of the general formula:
with nitrous acid.
12. A process as defined in claim 11, wherein said R group is branched at the C2 position.
13. A process as defined in claim 11, wherein said R group is branched at the C3 position.
14. A process as defined in claim 11, wherein said R group sterically conforms to a glutamine residue.
15. A compound of the general formula:
wherein R is an alkyl group of 3 to 8 carbon atoms with no branching at the Cl atom and Hal is selected from chlorine and fluorine, whenever prepared by the process of claim 11, or by an obvious chemical equivalent thereof.
wherein R is an alkyl group of 3 to 8 carbon atoms with no branching at the Cl atom and Hal is selected from chlorine and fluorine, whenever prepared by the process of claim 11, or by an obvious chemical equivalent thereof.
16. A compound of the general formula:
wherein R is an alkyl group of 3 to 8 carbon atoms with no branching at the C1 atom but branched at the C2 atom and Hal is selected from chlorine and fluorine, whenever prepared by the process of claim 12, or by an obvious chemical equivalent thereof.
wherein R is an alkyl group of 3 to 8 carbon atoms with no branching at the C1 atom but branched at the C2 atom and Hal is selected from chlorine and fluorine, whenever prepared by the process of claim 12, or by an obvious chemical equivalent thereof.
17. A compound of the general formula:
wherein R is an alkyl group of 3 to 8 carbon atoms with no branching at the Cl atom but branched at the C3 atom and Hal is selected from chlorine and fluorine, whenever prepared by the process of claim 13, or by an obvious chemical equivalent thereof.
wherein R is an alkyl group of 3 to 8 carbon atoms with no branching at the Cl atom but branched at the C3 atom and Hal is selected from chlorine and fluorine, whenever prepared by the process of claim 13, or by an obvious chemical equivalent thereof.
18. A compound of the general formula:
wherein R conforms to a glutamine residue and Hal is selected from chlorine and fluorine, whenever prepared by the process of claim 14, or by an obvious chemical equivalent thereof.
wherein R conforms to a glutamine residue and Hal is selected from chlorine and fluorine, whenever prepared by the process of claim 14, or by an obvious chemical equivalent thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/064,886 US4423076A (en) | 1979-08-08 | 1979-08-08 | 1-Branched-alkyl-3-(2-haloethyl)-3-nitrosoureas as novel antitumor agents |
US064,886 | 1979-08-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1179372A true CA1179372A (en) | 1984-12-11 |
Family
ID=22058871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000347028A Expired CA1179372A (en) | 1979-08-08 | 1980-03-05 | 1-branched-alkyl-3-(2-haloethy)-3-nitrosoureas as novel antitumor agents |
Country Status (14)
Country | Link |
---|---|
US (1) | US4423076A (en) |
JP (1) | JPS5653647A (en) |
AU (1) | AU532391B2 (en) |
CA (1) | CA1179372A (en) |
CH (1) | CH643237A5 (en) |
DE (1) | DE3020498A1 (en) |
DK (1) | DK281980A (en) |
FR (1) | FR2465716A1 (en) |
GB (1) | GB2056450B (en) |
HU (1) | HU182184B (en) |
IT (1) | IT1149819B (en) |
NL (1) | NL8001602A (en) |
NO (1) | NO151545C (en) |
SE (1) | SE8005574L (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5994668U (en) * | 1982-12-17 | 1984-06-27 | 三井造船株式会社 | emergency cutoff device |
GB9719426D0 (en) * | 1997-09-13 | 1997-11-12 | Johnson Matthey Plc | Novel process |
FR2768516B1 (en) * | 1997-09-16 | 1999-10-29 | Inst Bouisson Bertrand | USE OF ISOCYANATES FOR THE DETERMINATION OF NUCLEOPHILIC FUNCTIONS IN THE STATE OF TRACES IN A WET ENVIRONMENT |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4180655A (en) * | 1974-08-08 | 1979-12-25 | Tetsuo Suami | Nitrosourea derivatives |
US4039578A (en) * | 1976-03-08 | 1977-08-02 | Suami T | 1-Tetrahydroxycyclopentyl-3-nitroso-3-(2-chloroethyl)-urea antitumor agents |
US4148921A (en) * | 1977-07-13 | 1979-04-10 | Suami T | Antitumor agents |
-
1979
- 1979-08-08 US US06/064,886 patent/US4423076A/en not_active Expired - Lifetime
-
1980
- 1980-03-05 CA CA000347028A patent/CA1179372A/en not_active Expired
- 1980-03-18 NL NL8001602A patent/NL8001602A/en not_active Application Discontinuation
- 1980-04-01 AU AU57038/80A patent/AU532391B2/en not_active Ceased
- 1980-04-21 JP JP5279780A patent/JPS5653647A/en active Pending
- 1980-04-28 FR FR8009493A patent/FR2465716A1/en active Granted
- 1980-05-30 DE DE19803020498 patent/DE3020498A1/en not_active Withdrawn
- 1980-06-13 CH CH455580A patent/CH643237A5/en not_active IP Right Cessation
- 1980-06-30 DK DK281980A patent/DK281980A/en not_active Application Discontinuation
- 1980-08-05 NO NO802348A patent/NO151545C/en unknown
- 1980-08-06 SE SE8005574A patent/SE8005574L/en not_active Application Discontinuation
- 1980-08-07 IT IT24040/80A patent/IT1149819B/en active
- 1980-08-07 GB GB8025813A patent/GB2056450B/en not_active Expired
- 1980-08-07 HU HU801963A patent/HU182184B/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE3020498A1 (en) | 1981-02-26 |
NL8001602A (en) | 1981-02-10 |
GB2056450A (en) | 1981-03-18 |
NO151545B (en) | 1985-01-14 |
FR2465716A1 (en) | 1981-03-27 |
AU5703880A (en) | 1981-02-12 |
AU532391B2 (en) | 1983-09-29 |
JPS5653647A (en) | 1981-05-13 |
SE8005574L (en) | 1981-02-09 |
CH643237A5 (en) | 1984-05-30 |
HU182184B (en) | 1983-12-28 |
NO802348L (en) | 1981-02-09 |
GB2056450B (en) | 1983-04-07 |
DK281980A (en) | 1981-02-09 |
NO151545C (en) | 1985-05-02 |
FR2465716B1 (en) | 1983-07-08 |
US4423076A (en) | 1983-12-27 |
IT1149819B (en) | 1986-12-10 |
IT8024040A0 (en) | 1980-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3325361A (en) | Anticonvulsant agents | |
US4296105A (en) | Derivatives of doxorubicine, their preparation and use | |
Rosowsky et al. | Lipophilic 5'-alkyl phosphate esters of 1-. beta.-D-arabinofuranosylcytosine and its N4-acyl and 2, 2'-anhydro-3'-O-acyl derivatives as potential prodrugs | |
US5637619A (en) | Antitumor 2-aminocarbonyl-1, 2-bis(methylsulfonyl)-1-(substituted)hydrazines | |
EP0270349A2 (en) | Use of an anti-neoplastic spermine derivative in the preparation of a pharmaceutical composition | |
CA1179372A (en) | 1-branched-alkyl-3-(2-haloethy)-3-nitrosoureas as novel antitumor agents | |
Baiocchi et al. | Studies on methylglyoxal bis (guanylhydrazone) 1 analogs. II. Structural variations on methylglyoxal bis (guanylhydrazone) 2 | |
EP0181592B1 (en) | Use of spergualin derivatives for the preparation of medicaments having immunosuppressive activity | |
CA1099287A (en) | Inosadiamine derivatives | |
EP0409845A1 (en) | Method for protection from chemotherapeutic side effects | |
GB2034704A (en) | 2,6-daiminonebularines | |
JPS6220183B2 (en) | ||
HU203246B (en) | Process for producing antitumoural platinum(iv)-diamine complex and pharmaceutical compositions comprising such compound as active ingredient | |
VOGLER et al. | Autologous bone marrow transplantation with alkyl-lysophospholipid-purged marrow | |
US4423236A (en) | 5,6,-0-Isoalkylidene ascorbic acid derivatives | |
NL194916C (en) | Mitomycin phosphate derivatives. | |
US4707498A (en) | Fluorinated diaminoalkyne derivatives | |
EP0062329B1 (en) | Novel nitrosourea derivative, process for preparing same and therapeutic composition containing said derivate | |
EP0357109A2 (en) | Platinum-(II)-diamine complex, method for the preparation of this compound, preparation with an anti-tumour action which contains this compound and also shaped preparations with an anti-tumour action | |
WO1982000644A1 (en) | 5,6-o-isoalkylidene ascorbic acid derivatives | |
EP0378706B1 (en) | 5-substituted uridine derivatives and intermediates for their preparation | |
US4920126A (en) | Barbituric acid derivative and treatment of leukemia and tumors therewith | |
US4820706A (en) | Pteridine derivatives and method of treating leukemia employing same | |
EP0210291A1 (en) | Platinum complexes of antitumor agents | |
MacDiarmid et al. | Synthesis and properties of bis (2, 2-dimethylaziridinyl) phosphinic amides: a series of new antineoplastic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |